Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06928675

Cell-free DNA in Acute Stroke

Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Basel

Basel, 4031, Switzerland

Location status: Recruiting

Location contact

Gerrit Grosse, PD Dr. Dr.

CONTACT

[email protected]

+41 61 32 85265

Gerrit Grosse, PD Dr. Dr.

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan)
  • 18 years of age

Exclusion criteria

  • Patients currently undergoing immunological therapies.
  • Patients with immunological diseases
  • Patients with systemic infections at the time of admission

Treatment and study plan

Primary outcomes

  1. Stroke Etiology

    Time frame: at day 1

    Descriptive comparison of cell-free DNA in cerebral thrombi regarding stroke etiology

Secondary outcomes

  1. Correlation cfDNA concentration and perfusion outcome

    Time frame: at day 1

    cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including perfusion outcome

  2. Correlation cfDNA concentration and secondary embolism

    Time frame: at day 1

    cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including secondary embolism

  3. Correlation cfDNA concentration and thrombus fragmentation.

    Time frame: at day 1

    cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including thrombus fragmentation

  4. Measures of cfDNA as a marker of systemic inflammation

    Time frame: at day 1

    to correlate cfDNA amount in blood and thrombi

  5. 90-day functional outcomes

    Time frame: up to 3 month

    to examine the association between cfDNA concentrations in blood and thrombi with 90-day functional outcomes.

    To assess functional outcomes, the modified Rankin Scale (mRS) is evaluated via a structured telephone interview on day 90. A favorable outcome is defined as an mRS score of 0 to 2 points, while an unfavorable outcome is defined as an mRS score of 3 to 5 points.

Study contacts

Contact information is provided by the study sponsor or research team.

Gerrit Grosse, PD Dr. Dr.

CONTACT

[email protected]

+41 61 32 85265

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Official study title

CANTO - Cell-free DNA in Acute Stroke

Acronym: CANTO

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 15, 2025
Registry last updated
Apr 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.